New Lipopeptide Platform for Delivering Peptides and Proteins Into Cells
Novel peptide gemini surfactants with lysine-based sequences outperform the established R8 cell-penetrating peptide in delivering therapeutic peptides to the cytoplasm.
Quick Facts
What This Study Found
CP-PGs with tri-lysine sequences (DKCK12-K3 and DKCK12-K5) showed lower cytotoxicity and superior peptide delivery compared to the well-established R8 cell-penetrating peptide.
Key Numbers
EC50: 5.8-6.2 µM (best) vs 6.8 µM (R8); IC50: 198-241 µM (K3) vs 88 µM (R3); two C12 chains
How They Did This
Peptide synthesis, cytotoxicity assays on NIH3T3 cells, proapoptotic peptide (PAD) delivery assays measuring cell death as a functional readout of cytosolic delivery.
Why This Research Matters
Getting therapeutic peptides inside cells remains a major drug delivery challenge. These new carriers achieve better delivery than established CPPs while maintaining low toxicity.
The Bigger Picture
This PG-surfactant molecular framework offers a new platform for designing cell-penetrating carriers, expanding the toolkit for intracellular peptide and protein drug delivery.
What This Study Doesn't Tell Us
In vitro only using a single cell line. Functional readout based on apoptotic activity rather than direct delivery measurement. No in vivo data.
Questions This Raises
- ?Do CP-PGs maintain their carrier ability in vivo?
- ?Can this platform deliver larger proteins effectively?
- ?How does delivery efficiency compare across different cell types?
Trust & Context
- Key Stat:
- 6.2 μM EC50 DKCK12-K3 carrier ability for cytosolic peptide delivery, outperforming the established R8 CPP
- Evidence Grade:
- In vitro proof-of-concept comparing new carriers to an established standard. Early-stage but with quantitative performance data.
- Study Age:
- Published in 2020. Cell-penetrating peptide research continues to advance with new delivery platforms.
- Original Title:
- Development of Cell-Penetration PG-Surfactants and Its Application in External Peptide Delivery to Cytosol.
- Published In:
- Bioconjugate chemistry, 31(3), 821-833 (2020)
- Authors:
- Sumito, Natsumi, Koeda, Shuhei, Umezawa, Naoki, Inoue, Yasumichi, Tsukiji, Shinya, Higuchi, Tsunehiko, Mizuno, Toshihisa
- Database ID:
- RPEP-05151
Evidence Hierarchy
Frequently Asked Questions
Why is getting peptides into cells so difficult?
Cell membranes act as barriers that prevent most peptides from entering. Peptide drugs often need to reach targets inside cells but can't cross the membrane on their own. Cell-penetrating agents like these CP-PGs help shuttle therapeutic peptides across the membrane.
What makes these new carriers better?
The CP-PG carriers combine two alkyl chains with cationic peptide sequences in a unique architecture. The best variants delivered a therapeutic peptide more efficiently than the well-established R8 peptide while causing less cell damage.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05151APA
Sumito, Natsumi; Koeda, Shuhei; Umezawa, Naoki; Inoue, Yasumichi; Tsukiji, Shinya; Higuchi, Tsunehiko; Mizuno, Toshihisa. (2020). Development of Cell-Penetration PG-Surfactants and Its Application in External Peptide Delivery to Cytosol.. Bioconjugate chemistry, 31(3), 821-833. https://doi.org/10.1021/acs.bioconjchem.9b00877
MLA
Sumito, Natsumi, et al. "Development of Cell-Penetration PG-Surfactants and Its Application in External Peptide Delivery to Cytosol.." Bioconjugate chemistry, 2020. https://doi.org/10.1021/acs.bioconjchem.9b00877
RethinkPeptides
RethinkPeptides Research Database. "Development of Cell-Penetration PG-Surfactants and Its Appli..." RPEP-05151. Retrieved from https://rethinkpeptides.com/research/sumito-2020-development-of-cellpenetration-pgsurfactants
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.